Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).

At a median of 8.4 years from diagnosis to first sample, 8/83 (10%) were MRD-positive at any timepoint and 4/83 (5%) were positive at study entry. All 5 patients with distant metastatic recurrence were MRD-positive, with ctDNA lead times up to 37.6 months. Two of 8 MRD-positive patients had not recurred at latest follow-up.

ASCO Annual Meeting 2022PubMed 35658506